Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

doi:10.1172/JCI198193

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

The Journal of clinical investigation - 1 Apr 2026

Paschalis Alec, Figueiredo Ines, Bogdan Denisa, Lundberg Arian, Santos Rita, Gurel Bora, Taha Tarek, Longoria Ossian, Ferreira Ana, Bertan Claudia, Brittain Nicholas, Nelson Ryan, Walker Laura, Neeb Antje, Welti Jonathan, Yuan Wei, Mitsopoulos Costas, Plymate Stephen R, Haffner Michael C, Sowalsky Adam G, Carreira Suzanne, Sharp Adam, Gaughan Luke, de Bono Johann

Abstract excerpt

New androgen receptor (AR) pathway inhibitors (ARPIs) in clinical development, including AR degraders and CYP11A inhibitors, largely target ligand-dependent AR activation and have reported antitumor activity in metastatic castration-resistant prostate cancer (mCRPC) resistant to established ARPIs, predominately against tumors with AR mutations. We hypothesized that AR-mutated mCRPC exhibits lower AR splice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Gene Expression Regulation, Neoplastic

Share to Neoplasm Metastasis

Share to Neoplasm Proteins

Share to Prostatic Neoplasms, Castration-Resistant

Share to Protein Isoforms

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 41919503
DOI: 10.1172/JCI198193
PMCID: PMC13038193

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.PMID 41919503Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

Decoding the androgen receptor splice variants.Semantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

AR Splicing Variants and Resistance to AR Targeting AgentsSemantic proximity Read ↗

<scp>Androgen receptor</scp> splice variant 7 in castration‐resistant prostate cancer: Clinical considerationsSemantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

Androgen receptor splice variants and prostate cancer: From bench to bedsideSemantic proximity Read ↗

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.Semantic proximity Read ↗

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate CancerSemantic proximity Read ↗

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.Semantic proximity Read ↗

Role of androgen receptor splice variants in prostate cancer metastasisSemantic proximity Read ↗

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.